Glioblastoma, IDH-wildtype Clinical Trials

17 studies are recruiting for glioblastoma, idh-wildtype in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

   This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade IV glioblastoma or gliosarcoma that can be removed by surgery (resectable) and that is growing, spr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

   Locations

   2 in total

   Run by

   Jonsson Comprehensive Cancer Center

   See if you can join NCT07089641 on ClinicalTrials.gov

2. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

   This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Precision NextGen Oncology, Beverly Hills, California

   Locations

   8 in total

   Run by

   Neonc Technologies, Inc.

   See if you can join NCT06047379 on ClinicalTrials.gov

3. Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

   This phase III trial compares temporally-modulated pulsed radiation therapy versus standard radiation therapy in treating patients with newly diagnosed, IDH wildtype, MGMT-unmethylated glioblastoma. After completion of surgery, the standard of care for glioblastoma is radiation therapy. Radiation t…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California

   Locations

   54 in total

   Run by

   NRG Oncology

   See if you can join NCT07452458 on ClinicalTrials.gov

4. Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

   This phase II trial compares the effect of adding WSD0922-FU to temozolomide versus temozolomide alone in slowing disease progression in patients with Epidermal Growth Factor Receptor (EGFR)-mutant, IDH-wildtype glioblastoma. Temozolomide is in a class of medications called alkylating agents. It wo…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Locations

   3 in total

   Run by

   Mayo Clinic

   See if you can join NCT07708961 on ClinicalTrials.gov

5. Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

   This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI)…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

   Locations

   18 in total

   Run by

   ECOG-ACRIN Cancer Research Group

   See if you can join NCT06319027 on ClinicalTrials.gov

6. Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

   This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) levels and improve survival. Glioblastoma is the most common malignant primary brain tumor in adults, with an average survival time of approximat…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Locations

   3 in total

   Run by

   Mayo Clinic

   See if you can join NCT07091864 on ClinicalTrials.gov

7. WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

   This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma. Glioblastoma is difficult to treat effectively because the cells within the tumor vary widely and are controlled by factors within and around the tumor, requiring multi…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   2 in total

   Run by

   Northwestern University

   See if you can join NCT05879250 on ClinicalTrials.gov

8. Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

   This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse (progressive). Immunotherapy with monoclonal antibodies, such as retifanlima…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT07468136 on ClinicalTrials.gov

9. A Study of 177Lu-PSMA-617 in People With Gliomas

   The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07223034 on ClinicalTrials.gov

10. Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

    Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with me…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Lenox Hill Brain Tumor Center, New York, New York

    Run by

    Northwell Health

    See if you can join NCT05271240 on ClinicalTrials.gov

11. GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

    This phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma that has come back after a period of improvement (recurrent) or that is growing, spreading, or g…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT07301268 on ClinicalTrials.gov

12. Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

    The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Henry Ford Hospital, Detroit, Michigan

    Locations

    8 in total

    Run by

    Orbus Therapeutics, Inc.

    See if you can join NCT05879367 on ClinicalTrials.gov

13. The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

    Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival. However, the demonstrated safety profile of this approach is contradictory in the literature and the specific benefits in distinct clinical and molec…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    8 in total

    Run by

    Jasper Gerritsen

    See if you can join NCT06283927 on ClinicalTrials.gov

14. The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

    A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients. Recent results suggest that resection of the non-contrast-enhancing (NCE) part might yield even better survival outcomes (supramaximal resection, SMR). T…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    University of California, San Francisco (UCSF), San Francisco, California

    Locations

    8 in total

    Run by

    Jasper Gerritsen

    See if you can join NCT06118723 on ClinicalTrials.gov

15. The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

    Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site. To pursue maximal resection in a safe manner, mapping methods have been developed to test for motor and language function during the operation. Previous ev…

    Stage

    Not phased

    Ages

    Up to 90

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    8 in total

    Run by

    Erasmus Medical Center

    See if you can join NCT06273176 on ClinicalTrials.gov

16. The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

    There are no guidelines or prospective studies defining the optimal surgical treatment for gliomas of older patients (≥70 years) or those with limited functioning performance at presentation (KPS ≤70). Therefore, the decision between resection and biopsy is varied, amongst neurosurgeons internation…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    8 in total

    Run by

    Jasper Gerritsen

    See if you can join NCT06146725 on ClinicalTrials.gov

17. The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)

    There is no consensus on the optimal treatment of patients with high-grade glioma, especially when patients have limited functioning performance at presentation (KPS ≤70). Therefore, there are varied practice patterns around pursuing biopsy, resection, or palliation (best supportive care). This stu…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    8 in total

    Run by

    Jasper Gerritsen

    See if you can join NCT06146738 on ClinicalTrials.gov